Research PaperJournal of Pharmacology and PharmacotherapeuticsVol. 5 | Issue 2 | 2014 | pp. 100–138Open access
Identification of risk factors for carbamazepine‑induced serious mucocutaneous adverse reactions: A case‑control study using data from spontaneous adverse drug reaction reports
- 1*,
- 2,
- 1
- 1 Department of Medical Sciences, Uppsala University.
- 2 Uppsala Drug Information Center, Uppsala County Council, Uppsala, Sweden.
Published in Journal of Pharmacology and Pharmacotherapeutics
Correspondence: Ilma Bertulyte
Department of Medical Sciences, Uppsala University.
Email: ilma.bertulyte@akademiska.se
Copyright: © 2014 Manuscript Technomedia LLP. This is an open access article.
- Published:
- Jan 1, 2014
- Received:
- May 13, 2013
How to cite
Bertulyte, I., Schwan, S., & Hallberg, P. (2014). Identification of risk factors for carbamazepine‑induced serious mucocutaneous adverse reactions: A case‑control study using data from spontaneous adverse drug reaction reports. Journal of Pharmacology and Pharmacotherapeutics, 5(2), 100–138. https://doi.org/10.4103/0976-500X.130051
Abstract
Objectives: To identify risk factors other than genetic for severe carbamazepine-induced mucocutaneous reactions, that is, SJS, TEN, and exfoliative dermatitis (ED). Materials and Methods: We did a case‑control study using data from the Swedish national database of spontaneously reported adverse drug reactions (ADRs). We selected all patients who had been reported from January 1, 1965 to March 31, 2010 as having experienced SJS (n = 78), TEN (n = 6), or ED (n = 8), and assessed as at least possibly related to carbamazepine. We also included diagnoses possibly representative of early signs of these serious conditions, that is, erythema multiforme (EM, n = 34) and scaly rash (n = 13). We compared data on demographics, drug treatment, and clinical features for these patients (cases, n = 139) with those from patients who had experienced any other type of ADR from carbamazepine during the same time period (controls, n = 887). Results: After adjustment for multiple comparisons, alcohol abuse was statistically significantly more common among cases than controls (34.5% vs 8.7%, odds ratio 5.5 [95% confidence interval 3.6-8.4], P = 3.14 × 10‑14). The same was seen for SJS and EM individually. Conclusion: Alcohol abuse is a possible risk factor for serious carbamazepine‑induced mucocutaneous reactions.
Keywords
Subject
Article metadata
| Title | Identification of risk factors for carbamazepine‑induced serious mucocutaneous adverse reactions: A case‑control study using data from spontaneous adverse drug reaction reports |
|---|---|
| Authors | Ilma Bertulyte; Sofie Schwan; Pär Hallberg |
| Affiliations | Department of Medical Sciences, Uppsala University.; Uppsala Drug Information Center, Uppsala County Council, Uppsala, Sweden. |
| Corresponding author | ilma.bertulyte@akademiska.se |
| Journal | Journal of Pharmacology and Pharmacotherapeutics |
| Volume / Issue | Vol. 5, Issue 2 (2014) |
Also in this issue
- Why patients in pain cannot get “God’s own medicine?”pp. 81–2
- Switch over from intravenous to oral therapy: A concise overviewpp. 83–87
- Off‑label use of medicine: Perspective of physicians, patients, pharmaceutical companies and regulatory authoritiespp. 88–92
- Folic acid supplementation on homocysteine levels in children taking antiepileptic drugs: A randomized controlled trialpp. 93–94
- Assessment of demographics, treatment strategies, and evidence‑based medicine use among diabetic and non‑diabetic patients with acute coronary syndrome: A cohort studypp. 139–144
Readers Also Viewed
Development and Validation of UV/visible Spectrophotometric Method for Estimation of Piroxicam from Bulk and Formulation
Sandip Mohan Honmane, Kunal Rajaram Yadav, Yuvraj Dilip Dange
Apr 23, 2025
Effects of Artificial Intelligence on Academic Performance of Library and Information Science University Students: A Meta-Analysis (2023-2025)
Kayode Sunday John Dada
Aug 6, 2026
Bridging Innovation and Impact: A Multidisciplinary Approach to Contemporary Research Challenges
Mueen Ahmed KK
Aug 11, 2026